BeahmNPSmythDJTsuyukiRT.Outcomes of Urinary Tract Infection Management by Pharmacists (RxOUTMAP): a study of pharmacist prescribing and care in patients with uncomplicated urinary tract infections in the community. Can Pharm J (Ott)2018;151(5):305-314.
2.
HughesCYoongDGiguèrePHullMTanDHS. Canadian guideline on HIV preexposure prophylaxis and nonoccupational postexposure prophylaxis for pharmacists. Can Pharm J (Ott)2019;152(2):81-91.
3.
BookerCMurphyALIsenorJE, et al. Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV). Can Pharm J (Ott)2023;156(3):137-49.
4.
MarraCJohnstonKSantschiVTsuyukiRT.Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J (Ott)2017;150(3):184-97.
5.
TsuyukiRTRosenthalMPearsonGJ.A randomized trial of a community-based approach to dyslipidemia management: pharmacist prescribing to achieve cholesterol targets (RxACT Study). Can Pharm J (Ott)2016;149(5):283-92.
6.
Al HamarnehYNJohnstonKMarraCATsuyukiRT.Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the RxEACH study. Can Pharm J (Ott)2019;152(4):257-66.
7.
Al HarmarnehYNLambSDonaldM, et al. Pharmacist prescribing and care improves cardiovascular risk, but what do patients think? A substudy of the RxEACH study. Can Pharm J (Ott)2018;151(4):223-7.
8.
Al HamarnehYNOkadaHTsuyukiRT.Real-world implementation of diabetes management by pharmacists: the RXING Practice Tool. Can Pharm J (Ott)2021;154(3):160-65.
9.
TsuyukiRTDaviesNM.Self-denigration in pharmacy: words to banish from the pharmacy lexicon. Can Pharm J (Ott)2014;147(4):197-9.
10.
DaviesNMTsuyukiRT.Self-denigration in pharmacy: actions that should be curtailed. Can Pharm J (Ott)2014;147(5):265-6.
11.
TsuyukiRTHouleSKDOkadaH.Time to give up on expanded scope of practice. Can Pharm J (Ott)2018;151(5):286.
12.
WatsonKEAl HamarnehYNRabiDDaskalopoulouSSTsuyukiRT.Hypertension Canada’s 2020 hypertension guidelines for pharmacists: an update. Can Pharm J (Ott)2021;154(1):19-25.
13.
BabadagliHEBarryARThanassoulisGPearsonGJ.Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. Can Pharm J (Ott)2023;156(3):117-27.
14.
TkachukSReadyEChanS, et al. Role of the pharmacist caring for people at risk of or living with HIV in Canada. Can Pharm J (Ott)2024;157(5):218-39.
15.
TsuyukiRTWatsonKE.Taking primary care pharmacy to the next level. Can Pharm J (Ott)2023;156(2):52-3.
16.
TsuyukiRT.Workplace pressures and pharmacists under duress. Can Pharm J (Ott)2024;157(6):277-9.
17.
BishopAZwickerB.Addressing workplace stress and understaffing: the Nova Scotia approach. Can Pharm J (Ott)2025;158(1):4-6.
18.
RosenthalMAustinZTsuyukiRT.Are pharmacists the ultimate barrier to pharmacy practice change?Can Pharm J (Ott)2010;143(1):37-42.
19.
SuzukiSNishikawaYNakayamaTOkadaH.Pharmacist accessibility for non-native Japanese speakers: a cross-sectional study in Japan. Can Pharm J (Ott). Epub ahead of print 16 January 2025. DOI: 10.1177/17151635241305375.
20.
HadiMAAlbabtainBBawazeerG, et al. Patients’ views and experiences of the first community pharmacy-based medication therapy management clinic in the Middle East and North Africa (MENA): a qualitative study. Can Pharm J (Ott)2025;158(2):110-19.
21.
NindJMarraCAScahillSSiermansCSmithA.Does the type of pharmacy used influence medication adherence? A retrospective observational study in Aotearoa, New Zealand. Can Pharm J (Ott)2024;157(5):261-70.
22.
AdamsAJ.Regulating pharmacist services: achieving a full scope of practice. Can Pharm J (Ott)2023;156(5):231-4.